Drug Information

Drug General Information
Drug ID
D0E2ZX
Former ID
DIB015417
Drug Name
SGN-CD70A
Drug Type
Antibody
Indication Non-hodgkin's lymphoma [ICD10:C85] Phase 1 [524874]
Company
Seattle genetics
Target and Pathway
Target(s) CD70 Target Info [549769]
KEGG Pathway Cytokine-cytokine receptor interaction
NetPath Pathway IL2 Signaling Pathway
TNFalpha Signaling Pathway
RANKL Signaling Pathway
Reactome TNFs bind their physiological receptors
References
Ref 524874ClinicalTrials.gov (NCT02216890) Safety Study of SGN-CD70A in Cancer Patients. U.S. National Institutes of Health.
Ref 549769SGN-CD70A, a novel and highly potent anti-CD70 ADC, induces double-strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL). Cancer Research 10/2014; 74(19 Supplement):2647-2647.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.